Accuray 3Q 2026: Revenue $86.52M, EPS $0.07 — 10-Q Summary
Accuray reported Q1 2026 revenue of $86.52M, down 8% YoY, with net income of $10.13M, driven by a debt-extinguishment gain. Product revenue fell 26%, while service revenue rose 4%. Americas and China saw declines, but EIMEA grew 9%. Gross margin increased to 30.1%.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger sell pressure, but the sizable backlog and service revenue growth provide a counterbalance.
Market read
Micro‑cap earnings release with mixed signals; short‑term traders may react to revenue decline, while longer‑term investors may focus on backlog and service mix.
What to watch
Backlog remains strong at $272M and service revenue grew, which may cushion longer‑term outlook.
Background
Accuray (ARAY) provides radiation therapy systems; the Q1 2026 filing is the first public release of these numbers.
Ticker impact
Q1 2026 earnings released showing 8% revenue decline and a swing to net income due to a debt‑extinguishment gain.
likely modest downside as investors price in lower product shipments despite a one‑time gain.
The primary disclosure of quarterly results for a micro‑cap introduces new data; revenue decline is material for short‑term traders.
Market effects
Highlights softness in medical device shipments in the Americas and China, potentially weighing peers in the radiotherapy equipment space.
Americas and China exposure may drag regional biotech/medtech indices.
Limited to niche medtech sector; unlikely to affect broader market.
Counterpoint
The one‑time debt‑extinguishment gain and higher service margin could support a short‑term bounce if investors view the earnings as a temporary dip.
Key entities
- CompanyAccuray Inc.
Medical device manufacturer reporting Q1 2026 results.
